Glioblastoma Standard Care

Maximal safe resection seeks to remove as much visible tumor as possible without causing unacceptable neurological injury. The balance is important because tumor location can limit how much tissue surgeons can safely remove, while neurological function influences later treatment and daily functioning. When complete removal is not feasible, biopsy can provide tissue for diagnosis and treatment planning.

Temozolomide is an alkylating agent that damages tumor-cell DNA, creating a mechanism for harming glioblastoma cells during treatment. Standard care places it alongside focal radiotherapy and continues it afterward as adjuvant therapy. This combined sequence links local radiation treatment with a systemic drug approach, while the patient’s clinical status and tumor features help guide its use.

Treatment is individualized rather than determined by tumor diagnosis alone. Clinicians consider clinical status, tumor location, molecular features, and treatment goals when selecting or adapting care. These factors can influence whether surgery or biopsy is appropriate, how aggressively neurological function can be preserved, and whether additional options such as tumor-treating fields fit the overall plan.

Tumor-treating fields may be added for selected patients as part of a broader treatment plan. The overview identifies this approach as an option beyond surgery, radiotherapy, and temozolomide, but does not specify selection criteria or outcomes. Its inclusion illustrates that standard care can incorporate additional modalities when clinicians judge them suitable for the individual patient.

Care generally begins with maximal safe surgical resection when feasible, or biopsy when tissue sampling is the safer or more appropriate route. Focal radiotherapy with concurrent temozolomide then follows, and temozolomide may continue as adjuvant treatment afterward. Clinicians coordinate this sequence with neurological preservation, molecular information, and the patient’s treatment goals.

Infection monitoring is an important part of care because both glioblastoma and its therapies can impair immune function. Clinicians watch for infectious complications while treatment proceeds and coordinate supportive measures alongside tumor-directed therapy. Corticosteroid-related complications also require attention, making immune status, steroid effects, and neurological management relevant to ongoing clinical decisions.

Immunology is relevant because the disease and its treatments may weaken immune function, increasing the importance of infection monitoring and supportive care. It also provides context for ongoing research into immunotherapies and other targeted strategies. These investigational directions complement, rather than replace, the established treatment sequence of surgery or biopsy, radiotherapy, and temozolomide.